SCC Research Publications

Recent Publications

Gonzales D. Nicotine patch plus lozenge gives greatest increases in abstinence from smoking rates at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined. Commentary on: Arch Gen Psychiatry 2009;66:1253-62. Evid Based Med 2010;15:77-78.

Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction2009;104:266-76

Gonzales D, Bjornson WG, Markin C. More than brief intervention: updating smoking cessation treatment for pulmonary patients. Pulmonary and Critical Care Update (PCCU) 2008;22 (Lesson 8).   

Gonzales D, Rennard SI, Jorenby DE, Reeves KR. Comment: Oral varenicline for smoking cessation. Ann Pharmacother 2007:41;720-721.

Gonzales D, Redtomahawk D, Pizacani B, Bjornson WG, Spradley J, Allen E, Lees P. Support for spirituality in smoking cessation: results of pilot survey. Nicotine Tob Res 2007; 9: 299-303.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J,Williams KE, Reeves KR, for the Varenicline Phase 3 Study Group. Varenicline an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial JAMA 2006;296:47-55.

Jorenby DE, Tonstad S, Gonzales D. Efficacy of Varenicline for Smoking Cessation -Reply. JAMA 2006;296: 2555-2556.

Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR, on behalf of the Varenicline Study Group. Smoking cessation with varenicline, a selective a4ß2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with one-year follow-up. Arch Intern Med 2006:166:1561-1568.

Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K, on behalf of the Varenicline Study Group. Efficacy and safety of the novel selective acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006:166:1571-1577.

Oncken CA, Gonzales D, Nides M, Rennard S, Watsky EJ, Coe JW. Varenicline: An a4ß2 nicotinic acetylcholine receptor partial agonist as an aid to smoking cessation. In T.P. George (Ed.), Medication Treatments for Nicotine Dependence. Boca Raton, Florida: Taylor & Francis 2006: 343-360.

Publication Archives

View the SCC Publication Archives